Open access
Aug 2026
Ascomycin enhances the antitumor activity of osimertinib in EGFR-TKI-resistant non-small cell lung cancer
Background Resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) remains a major challenge in non-small cell lung cancer (NSCLC) treatment. Although ascomycin (FK520) has demonstrated some antitumor activity, its potential in overcoming osimertinib resistance has not been fully character...
Hong-Bing Zhang, Chen Chen, Di Wu et al.
· Frontiers in Oncology · 0 citations